- PDF: Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)
Multiple Sclerosis: KOL Insight
- Publication Date:September 2013
- Product Type: Report
Multiple Sclerosis: KOL InsightThe multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera (dimethyl fumarate) has revolutionised multiple sclerosis treatment in the US, eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera's launch in Europe. Genzyme have taken advantage of this delay with Lemtrada's (alemtuzumab) and Aubagio's (teriflunomide) EU approval. The arrival of these drugs is expected to revolutionise multiple sclerosis treatment and be a catalyst for unprecedented market growth.
Driven by in-depth interviews with the world's leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.
Multiple Sclerosis: The oral era begins examines the most prominent insights gained from the field's key opinion leaders. Key benefits include:
Multiple Sclerosis: The oral era begins answers key questions including:
Reasons to Buy this Report
Multiple Sclerosis Panel of Key Opinion Leaders
The MS KOL panel assembled for this Therapy Trends research is drawn from North America, Europe and Australia
Stay a step ahead with Therapy Trends Event Assessments. Over the next 12 months, you will receive updated qualitative analysis every time a major market event breaks. Updates will be delivered straight into your inbox within days of each event's occurrence.
Whether it's a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
This report provides a qualitative assessment of the current and future Multiple Sclerosis market. Information was gathered from in-depth telephone interviews with twelve key opinion leaders (KOLs), from across the major Multiple Sclerosis markets, including Australia, Canada, France, Germany, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also dictate the dynamics of Pharma markets in other countries.
In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.
Subject matter for discussion in the interviews covered future diagnostic and therapeutic strategies for Multiple Sclerosis, the future drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing drug classes, the cost of newer drugs and other concerns in the therapy area.